Forbes Contributor Prescribes Important Changes to Improve Information Sharing in Our Healthcare System

07.16.14 | By

Continuing an important conversation about how to make the best use of the wealth of information regarding today’s healthcare treatment options, last week Nicole Fisher wrote in Forbes about the growing need for a new regulatory paradigm to govern how the biopharmaceutical industry communicates with healthcare professionals about medicines.

340B: Keeping a Promise to Patients

07.16.14 | By

The 340B program was created to help vulnerable and uninsured patients access needed medicines. However, the program continues to grow exponentially without appropriate guardrails, putting it at risk. Appropriate oversight and reform is needed to ensure the 340B program can fulfill its promise to patients.

The Voices of Schizophrenia and the Potential in the Pipeline

07.15.14 | By

Around 2.4 million American adults have schizophrenia each year and onset can be caused by a combination of genetic predisposition and external stressors. Learn more about the 119 medicines in development for mental health.

Overcoming Obstacles to Future Innovation

07.15.14 | By

What would happen if the pace of medical innovation in the U.S. slowed or halted altogether? Imagine the treatments and cures that will never come, for Alzheimer’s, for Parkinson’s, for cancers of all kinds.  Imagine also the economic impact: on productivity, on medical costs for people who have conditions without good treatments, on a biopharmaceutical industry that accounts for nearly one out of every five dollars spent on R&D by U.S. businesses and that supports $790 billion in total annual economic activity.

Limiting Access to Necessary Medicines Threatens Hope for Oncology Patients

07.15.14 | By

Patients, especially those suffering from chronic conditions, deserve access to the medicines they need to live longer, healthier lives. The Affordable Care Act’s health insurance exchanges and the Essential Health Benefits they’re meant to provide were supposed to ensure patients have access to the treatments they need. But for many, high out-of-pocket costs create a sometimes insurmountable barrier to access.

TTIP Negotiations Toward Better Health Outcomes

07.15.14 | By

This week, the European Commission hosts the sixth negotiating round of the Transatlantic Trade and Investment Partnership (TTIP) in Brussels.  As the Commission notes on its website, the discussions will focus on major issue areas including “trade in goods and services, regulatory issues, government procurement, environmental protection and labor rights, energy and raw materials, and opportunities for small- and medium-sized enterprises (SMEs).”  This round, as in the past, will also include a dedicated day for stakehol

The Price of NOT Curing Hepatitis C

07.14.14 | By

“Over the next 20 years, total annual medical costs for patients with HCV infection are expected to more than double, from $30 billion to over $85 billion.”

Week in Review: It’s All About Patients

07.11.14 | By

For biopharmaceutical companies, patients are our priority. Throughout the research and development process, it is our job to make sure that innovative, new treatments are moving through the pipeline, into the hands of those in need. To achieve this, a number of different issues must be addressed across the U.S. and around the world. This week, the Catalyst touched on a variety of topics that aren’t typically top-of-mind, but represent just a small sample of issues that are important to helping patients live longer, healthier lives.

Cost-Effectiveness Standards in the UK Lead to Restrictions in Patient Access to Cancer Therapies

07.11.14 | By

The debate over the cost and value of innovative medicines has prompted some to make renewed calls for use of a cost-effectiveness or similar standard in the U.S. One example of this was highlighted in a recent column by Ed Silverman at the Wall Street Journal.

UK Cancer Patients Face Increasing Coverage Restrictions Due to Centralized Cost-Effectiveness Standard, New Report Shows

Washington, D.C.


Subscribe to RSS - Opinion